Faeth Therapeutics (FTH) Operating Income (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Operating Income came in at -$170.6 million in Q1 2026, down 2245.71% YoY from $8.0 million in Q1 2025, and down 3342.14% on a QoQ basis from -$5.0 million in Q4 2025.
Faeth Therapeutics (FTH) Operating Income (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Operating Income data on file, last reported at -$170.6 million in Q1 2026.
- Quarterly Operating Income fell 2245.71% year-over-year to -$170.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$185.6 million (down 495.81% YoY) and the FY2025 annual result came in at -$22.3 million, up 31.66% from the prior year.
- Operating Income eased to -$170.6 million in Q1 2026, from -$5.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$4.9 million in Q3 2025 to a low of -$170.6 million in Q1 2026.
- A 5-year average of -$18.4 million and a median of -$8.3 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income surged 44.5% — and 2026, when it tumbled 2245.71%.
- Tracing FTH's Operating Income over 5 years: stood at -$13.0 million in 2022, then surged by 37.6% to -$8.1 million in 2023, then declined by 1.62% to -$8.3 million in 2024, then jumped by 40.09% to -$5.0 million in 2025, then sank by 3342.14% to -$170.6 million in 2026.
- The last three Operating Income figures came in at -$170.6 million (Q1 2026), -$5.0 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Faeth Therapeutics | 180.89 Mn | 180.89 Mn | - | -18.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.39 Mn |
| Mar 31, 2026 | -170.63 Mn |
| Dec 31, 2025 | -4.96 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -5.21 Mn |
| Mar 31, 2025 | -7.27 Mn |
| Dec 31, 2024 | -8.27 Mn |
| Sep 30, 2024 | -7.82 Mn |
| Jun 30, 2024 | -7.79 Mn |
| Mar 31, 2024 | -8.73 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -7.74 Mn |
| Jun 30, 2023 | -10.18 Mn |
| Mar 31, 2023 | -11.01 Mn |
| Dec 31, 2022 | -13.05 Mn |
| Sep 30, 2022 | -13.94 Mn |
| Jun 30, 2022 | -10.71 Mn |
| Mar 31, 2022 | -12.49 Mn |
| Dec 31, 2021 | -9.41 Mn |
| Sep 30, 2021 | -10.32 Mn |